MedPath

Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) Reconstruction

Phase 3
Completed
Conditions
Knee Injuries
Interventions
Drug: OMS103HP
Drug: Vehicle
Registration Number
NCT00226759
Lead Sponsor
Omeros Corporation
Brief Summary

The anterior cruciate ligament (ACL) is an important stabilizer of the knee. Orthopedic surgeons replace the torn ligament during ACL reconstruction surgery. Surgical trauma initiates an acute inflammatory response, including swelling and pain, that leads to restricted joint motion and loss of function. OMS103HP was designed to deliver targeted therapeutic agents directly to the surgical site during the arthroscopic procedure to inhibit inflammation and pain before they can begin.

The purpose of this study is to assess the effectiveness and safety of OMS103HP in improving knee function following ACL reconstruction. Secondary benefits being evaluated include reduced postoperative pain, improvement in knee range of motion and earlier return to work.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
321
Inclusion Criteria
  • 15 - 65 years of age
  • In good general health with an ACL tear that occurred from 2 weeks to 18 months prior to the day of arthroscopic surgery
  • Undergoing primary unilateral ACL reconstruction using an allograft (patellar tendon bone, Achilles tendon, tibialis tendon, or hamstring)
  • Able to participate in the study rehabilitation protocol
  • and other inclusion criteria
Exclusion Criteria
  • No allergies to any of the individual ingredients in OMS103HP
  • No medications with the same activities as that of the active ingredients in OMS103HP for defined time intervals prior to and after surgery
  • No associated knee injuries likely to interfere with evaluation of the study drug
  • and other exclusion criteria

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
OMS103HP irrigation solutionOMS103HPDrug
vehicle irrigation solutionVehicleVehicle
Primary Outcome Measures
NameTimeMethod
Improvement in knee function30 days
Secondary Outcome Measures
NameTimeMethod
Earlier return to work30 days
Decreased pain30 days
Improved range of motion30 days

Trial Locations

Locations (19)

Colorado Orthopedic Consultants, PC

๐Ÿ‡บ๐Ÿ‡ธ

Englewood, Colorado, United States

American Clinical Research Services

๐Ÿ‡บ๐Ÿ‡ธ

Steamboat Springs, Colorado, United States

Sports, Orthopedic and Rehabilitation Medicine Associates (S.O.A.R.)

๐Ÿ‡บ๐Ÿ‡ธ

Redwood City, California, United States

Unlimited Research

๐Ÿ‡บ๐Ÿ‡ธ

San Antonio, Texas, United States

Hill Country Sports Medicine

๐Ÿ‡บ๐Ÿ‡ธ

San Marcos, Texas, United States

Southeastern Center for Clinical Trials

๐Ÿ‡บ๐Ÿ‡ธ

Atlanta, Georgia, United States

Stanford University

๐Ÿ‡บ๐Ÿ‡ธ

Stanford, California, United States

Round Rock Orthopedics

๐Ÿ‡บ๐Ÿ‡ธ

Round Rock, Texas, United States

Hotel Dieu Grace Hospital

๐Ÿ‡จ๐Ÿ‡ฆ

Windsor, Ontario, Canada

Rouge Valley Health Systems

๐Ÿ‡จ๐Ÿ‡ฆ

Ajax, Ontario, Canada

Minnesota Sports Medicine

๐Ÿ‡บ๐Ÿ‡ธ

Minneapolis, Minnesota, United States

Texas Orthopedics

๐Ÿ‡บ๐Ÿ‡ธ

Austin, Texas, United States

University of Pittsburgh Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Pittsburgh, Pennsylvania, United States

CORE Orthopaedic Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Encinitas, California, United States

Ohio State University

๐Ÿ‡บ๐Ÿ‡ธ

Columbus, Ohio, United States

University Orthopedics Center

๐Ÿ‡บ๐Ÿ‡ธ

State College, Pennsylvania, United States

Naval Medical Center - Portsmouth

๐Ÿ‡บ๐Ÿ‡ธ

Portsmouth, Virginia, United States

Madigan Army Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Tacoma, Washington, United States

University of Florida

๐Ÿ‡บ๐Ÿ‡ธ

Gainesville, Florida, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath